The Prospects of tumor necrosis factor α inhibitors use in patients with COVID-19
The review highlights the problem of finding new effective treatment strategies for COVID-19. Tumor necrosis factor α (TNF-α) is considered as a therapeutic target. The theoretical basis for the successful use of TNF-α inhibitors (ITNFα) for the treatment of COVID-19 is presented, as well as data on...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2021-04-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1128 |
| _version_ | 1797876708727062528 |
|---|---|
| author | E. S. Aronova B. S. Belov |
| author_facet | E. S. Aronova B. S. Belov |
| author_sort | E. S. Aronova |
| collection | DOAJ |
| description | The review highlights the problem of finding new effective treatment strategies for COVID-19. Tumor necrosis factor α (TNF-α) is considered as a therapeutic target. The theoretical basis for the successful use of TNF-α inhibitors (ITNFα) for the treatment of COVID-19 is presented, as well as data on existing practical developments, including ongoing clinical trials. Two drugs from the group of ITNFα – infliximab and adalimumab – are currently being considered as possible options. The safety issues of ITNFα treatment in patients with immunophaling rheumatic diseases and COVID-19 are discussed. The review also provides current data on vaccination against COVID-19, in particular on the vaccines currently available in Russia, which are at different stages of clinical trials. We conclude that randomized clinical trials of the effectiveness and safety of ITNF-α in patients with the new coronavirus infection are needed. Such trials will promote transition from theoretical speculations to real clinical practice. |
| first_indexed | 2024-04-10T02:06:54Z |
| format | Article |
| id | doaj.art-ecbc8f8cb14e497282be305aed9eb73f |
| institution | Directory Open Access Journal |
| issn | 1996-7012 2310-158X |
| language | Russian |
| last_indexed | 2024-04-10T02:06:54Z |
| publishDate | 2021-04-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj.art-ecbc8f8cb14e497282be305aed9eb73f2023-03-13T08:39:28ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2021-04-01152899310.14412/1996-7012-2021-2-89-932349The Prospects of tumor necrosis factor α inhibitors use in patients with COVID-19E. S. Aronova0B. S. Belov1ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»The review highlights the problem of finding new effective treatment strategies for COVID-19. Tumor necrosis factor α (TNF-α) is considered as a therapeutic target. The theoretical basis for the successful use of TNF-α inhibitors (ITNFα) for the treatment of COVID-19 is presented, as well as data on existing practical developments, including ongoing clinical trials. Two drugs from the group of ITNFα – infliximab and adalimumab – are currently being considered as possible options. The safety issues of ITNFα treatment in patients with immunophaling rheumatic diseases and COVID-19 are discussed. The review also provides current data on vaccination against COVID-19, in particular on the vaccines currently available in Russia, which are at different stages of clinical trials. We conclude that randomized clinical trials of the effectiveness and safety of ITNF-α in patients with the new coronavirus infection are needed. Such trials will promote transition from theoretical speculations to real clinical practice.https://mrj.ima-press.net/mrj/article/view/1128коронавирусная инфекцияингибиторы фактора некроза опухоли αsars-cov-2covid-19иммуновоспалительные ревматические заболеванияинфликсимабадалимумаб |
| spellingShingle | E. S. Aronova B. S. Belov The Prospects of tumor necrosis factor α inhibitors use in patients with COVID-19 Современная ревматология коронавирусная инфекция ингибиторы фактора некроза опухоли α sars-cov-2 covid-19 иммуновоспалительные ревматические заболевания инфликсимаб адалимумаб |
| title | The Prospects of tumor necrosis factor α inhibitors use in patients with COVID-19 |
| title_full | The Prospects of tumor necrosis factor α inhibitors use in patients with COVID-19 |
| title_fullStr | The Prospects of tumor necrosis factor α inhibitors use in patients with COVID-19 |
| title_full_unstemmed | The Prospects of tumor necrosis factor α inhibitors use in patients with COVID-19 |
| title_short | The Prospects of tumor necrosis factor α inhibitors use in patients with COVID-19 |
| title_sort | prospects of tumor necrosis factor α inhibitors use in patients with covid 19 |
| topic | коронавирусная инфекция ингибиторы фактора некроза опухоли α sars-cov-2 covid-19 иммуновоспалительные ревматические заболевания инфликсимаб адалимумаб |
| url | https://mrj.ima-press.net/mrj/article/view/1128 |
| work_keys_str_mv | AT esaronova theprospectsoftumornecrosisfactorainhibitorsuseinpatientswithcovid19 AT bsbelov theprospectsoftumornecrosisfactorainhibitorsuseinpatientswithcovid19 AT esaronova prospectsoftumornecrosisfactorainhibitorsuseinpatientswithcovid19 AT bsbelov prospectsoftumornecrosisfactorainhibitorsuseinpatientswithcovid19 |